Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 987 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Blood Coagulation Disorder
Interventions
Hemosense (PT/InR point of care device)
Device
Lead sponsor
University of Rochester
Other
Eligibility
1 Day to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Conditions
ITP, Immune Thrombocytopenia
Interventions
Fostamatinib
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more
Conditions
Pediatric, Coagulation
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
Up to 17 Years
Enrollment
240 participants
Timeline
2026 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts
Conditions
Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
4 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Completed No phase listed Observational Accepts healthy volunteers Results available

Coagulation Factor Changes Associated With Postpartum Hysterectomies

NCT00456547
Conditions
Obstetric Labor Complications, Hemorrhage, Complications; Cesarean Section
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
rituximab
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more
Completed Phase 1Phase 2 Interventional Results available

A Gene Transfer Study for Hemophilia A

NCT03003533
Conditions
Hemophilia A
Interventions
SPK-8011
Genetic
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Sacramento, California • Gainesville, Florida • Boston, Massachusetts + 7 more
Conditions
Preeclampsia, Coagulation Disorder, Pregnancy Complications
Interventions
Thromboelastogram
Diagnostic Test
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Decitabine, Ruxolitinib, Fedratinib, Questionnaire Administration, Pacritinib, Biospecimen Collection
Drug · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Reversal of Coagulopathy
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
coagulation factor VIIa [recombinant]-jncw
Drug
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Conditions
Immune Thrombocytopenic Purpura
Interventions
rituxan
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Vahalla, New York
Conditions
Hemophilia A
Interventions
Moroctocog alfa(AF-CC), Blood draw for laboratory testing
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Completed Not applicable Interventional Results available

Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence

NCT02690649
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Health Messaging (Non-Procedural)
Other
Lead sponsor
Tammy Toscos
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Wayne, Indiana
Conditions
Hemophilia A
Interventions
ASC618
Biological
Lead sponsor
ASC Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Pharmacodynamic Study of Rivaroxaban

NCT01743898
Conditions
Blood Clot
Interventions
Rivaroxaban, no anticoagulation
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Hemophilia A
Interventions
BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Conditions
Congenital Bleeding Disorder, Glanzmann's Disease
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

NCT05006378
Conditions
Coagulation Disorder
Interventions
Chamomile Tea, Chamomile Extract Capsule, Placebo Capsule
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition, Precancerous Condition
Interventions
tanespimycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

BAX 855 Pediatric Study

NCT02210091
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 11 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more
Conditions
Hypofibrinogenemia, Bleeding
Interventions
Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Hemophilia A
Interventions
Kogenate (BAY 14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Detroit, Michigan • Las Vegas, Nevada